Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|February 25, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-05-2014
- Volume 10
- Issue 3
Almac Adds New Blistering Technology
Author(s)Pharmaceutical Technology Editors
Almac has added new blistering technology at their US packaging facility in Audubon, PA, as a solution to ease the transition between clinical and commercial launch of blister products.
Advertisement
Almac has added new blistering technology at their US packaging facility in Audubon, PA, as a solution to ease the transition between clinical and commercial launch of blister products. The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials.
Clients can now easily transition from the clinical blister presentation though various development packs. This offering provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost-effective stability packaging.
Source:
Articles in this issue
over 12 years ago
Top 10 Outsourcing Trends in Biopharmaceutical Manufacturingover 12 years ago
Local Knowledge Drives Global Market Expansionover 12 years ago
Regulatory Initiatives Spur API Supply Chain Securityover 12 years ago
Croda Receives Two EXCiPACT Certificationsover 12 years ago
Reaching China's Clinical Trial Marketover 12 years ago
MedImmune Announces Research Collaboration with UC SanFranciscoover 12 years ago
Inflammatory Diseases Explained in Artistic DesignsAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5